|
|
| | Sitagliptin phosphate monohydrate Basic information |
| Product Name: | Sitagliptin phosphate monohydrate | | Synonyms: | Sitagliptin phosphate monohydrate 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate monohydrate;Sitagliptin phosphate mon;Sitagliptin phosphate monohydrate, >=99%;(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4;Sitagliptin phosphate monohydrate;Sitagliptin phosphate for research;D06645;Januvia (tn) | | CAS: | 654671-77-9 | | MF: | C16H18F6N5O5P | | MW: | 505.31 | | EINECS: | 682-492-2 | | Product Categories: | Inhibitors;Inhibitor;API;APIs;654671-77-9 | | Mol File: | 654671-77-9.mol |  |
| | Sitagliptin phosphate monohydrate Chemical Properties |
| Fp | 274.3℃ | | storage temp. | 2-8°C | | solubility | ≥23.8 mg/mL in DMSO; insoluble in EtOH; ≥30.6 mg/mL in H2O with ultrasonic | | form | solid | | color | White to off-white | | InChIKey | IQFYVLUXQXSJJN-OVMXBOEKNA-N | | SMILES | P(O)(O)(O)=O.C(C1=NN=C2CN(C(=O)C[C@H](N)CC3C=C(F)C(F)=CC=3F)CCN12)(F)(F)F |&1:15,r| | | CAS DataBase Reference | 654671-77-9(CAS DataBase Reference) |
| | Sitagliptin phosphate monohydrate Usage And Synthesis |
| Chemical Properties | white crystalline | | Uses | antimuscarinic | | Uses | Sitagliptin Phosphate Monohydrate is a dipeptidyl peptidase-IV (DPPIV) inhibitor. | | Biological Activity | sitagliptin phosphate monohydrate is the phosphate salt of its active component, sitagliptin, with one molecule of water. sitagliptin is a potent inhibitor of dipeptidyl peptidase 4 (dpp-4), an enzyme catalyzing the cleavage of peptides with an n-terminal alanine or proline amino acid residue, that selectively inhibits dpp-4 with 50% inhibition concentration ic50 value of 18 nm and shows no affinity towards other ddp enzymes (such as ddp-8 and ddp-9). the inhibition of dpp4 by sitagliptin has been found to be mediated by increasing levels of two dpp-4 substrates, including glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip). sitagliptin is currently being investigated in the treatment of type ii diabetes.gallwitz b. review of sitagliptin phosphate: a novel treatment for type 2 diabetes. vasc health risk manag. 2007;3(2):203-10. | | target | DPP-4 |
| | Sitagliptin phosphate monohydrate Preparation Products And Raw materials |
|